Potential Preventive Strategies for Amyotrophic Lateral Sclerosis

Kuraszkiewicz, Bożenna; Goszczyńska, Hanna; Podsiadły-Marczykowska, T.; Piotrkiewicz, Maria; Andersen, Peter M.; Gromicho, Marta; Großkreutz, Julian; Kuźma‐Kozakiewicz, Magdalena; Petri, Susanne; Stubbendorf, B.; Szacka, Katarzyna; Uysal, Hilmi; Carvalho, Mamede de

doi:10.3389/fnins.2020.00428

Cited by 14 publications

(10 citation statements)

References 184 publications

(235 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A positive correlation of plasma leptin and body mass index (BMI) was observed in ALS patients (Ngo et al., 2015). This is of interest because patients with ALS are unable to maintain their body weight (Bouteloup et al., 2009; Desport et al., 2001), and rapid weight loss is clinically associated with worse disease outcomes (Ahmed et al., 2019; Kuraszkiewicz et al., 2020). Indeed, weight loss is a predictor of shorter survival in ALS (Lee et al., 2021), raising the possibility that leptin could be exploited to derive therapeutic effects.…”

Section: Introductionmentioning

confidence: 99%

The potential benefit of leptin therapy against amyotrophic lateral sclerosis (ALS)

et al. 2021

View full text Add to dashboard Cite

Background Targeting leptin could represent a rational strategy to treat amyotrophic lateral sclerosis (ALS), as previously clinical studies have shown its levels to be associated with a lower risk of ALS disease. However, very little is known about the potential influence of leptin in altering disease progression in ALS, as it has thus far been correlated with the protection exerted by increased fat mass stores. Methods We studied the impact of leptin treatment beginning at 42‐days of age (asymptomatic stage of disease) in the TDP‐43 (TDP43A315T) transgenic (Tg) ALS mouse model. Results Our study shows that leptin treatment was associated with altered expression of adipokines and metabolic proteins in TDP43A315T mice. We also observed that weight loss decline was less prominent after leptin treatment in TDP43A315T mice relative to vehicle‐treated animals. In TDP43A315T mice treated with leptin the disease duration lasted longer along with an improvement in motor performance relative to vehicle‐treated animals. Conclusions Collectively, our results support leptin as a potential novel treatment approach for ALS.

show abstract

Section: Introductionmentioning

confidence: 99%

The potential benefit of leptin therapy against amyotrophic lateral sclerosis (ALS)

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Various treatments are used to alleviate symptoms but there are only two pharmacologic agents indicated for the supervision of ALS. Riluzole in the year 1996 had Copyright © 2021 IR Research Publication -All Rights Reserved been the anchor for disease-modifying therapy, but in May 2017, a new agent Edaravone is approved by the FDA [11,14,16]. Various organizations are dedicated to work for multidisciplinary care by imparting aid for people with ALS-support, ALS Research and clinical trial, therapeutic progression for irregular and congenital forms of ALS.…”

Section: Treatmentmentioning

confidence: 99%

Amyotrophic lateral sclerosis is a complicated challenge that needs distinct evaluation

Mishra¹,

Sharma²,

Shanno³

et al. 2022

View full text Add to dashboard Cite

The Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that affects motor neuron and decreases muscle functionality. As it is a cumulative disease, it will eventually head to paralysis and unavoidably death. ALS often has a principal onset, but subsequently spreads to various body regions, where failure of respiratory muscles typically limits survival to 2-5 years after disease onset. The etiology of the ALS is still unclear. However, superoxide dismutase 1 mutations have been known to be the most frequent cause of Familial ALS (FALS). However, despite the low frequency, ALS is not especially infrequent. In up to 50% of cases, there are extra-motor manifestations such as changes in behaviour, executive dysfunction, and language problems. There is no cure for ALS up till now and the basis of treatment remains multidisciplinary care, including nutritional and respiratory support, and symptom management. Two medications, riluzole and edaravone, have proved effective for the symptomatic treatment with modest benefits, but there is urge for treatment options which can extend the survival rate of the patient. Further, we have discussed different aspects of ALS, including epidemiology, pathogenesis, clinical features, differential diagnosis, investigations, and treatment and future prospects.

show abstract

“…Furthermore, other factors including oxidative stress, mitochondrial dysfunction, and neuroinflammation are implicated in ALS pathologically. Neuroinflammation, via NF-κβ proinflammatory cellular pathway activation, plays a central role in ALS pathogenesis [13,59,60]. Several ALS patients had been shown an increased NF-κβ signaling expression in microglia.…”

Section: Amyotrophic Lateral Sclerosismentioning

confidence: 99%

“…Several ALS patients had been shown an increased NF-κβ signaling expression in microglia. Thus, through NF-κβ expression reducing in microglia can slow the progress of disease and lengthen the survival in ALS mouse models [60,61].…”

Section: Amyotrophic Lateral Sclerosismentioning

confidence: 99%

The Functional Roles of Curcumin on Astrocytes in Neurodegenerative Diseases

Mohammadi

Colagar

Khorshidian

et al. 2021

Neuroimmunomodulation

View full text Add to dashboard Cite

Progressive abnormality and loss of axons and neurons in the central nervous system (CNS) cause neurodegenerative diseases (NDs). Protein misfolding and its collection are the most important pathological features of NDs. Astrocytes are the most plentiful cells in the mammalian CNS (about 20–40% of the human brain) and have several central functions in the maintenance of the health and correct function of the CNS. Astrocytes have an essential role in the preservation of brain homeostasis, and it is not surprising that these multifunctional cells have been implicated in the onset and progression of several NDs. Thus, they become an exciting target for the study of NDs. Over almost 15 years, it was revealed that curcumin has several therapeutic effects in a wide variety of diseases’ treatment. Curcumin is a valuable ingredient present in turmeric spice and has several essential roles, including those which are anticarcinogenic, hepatoprotective, thrombosuppressive, cardioprotective, anti-arthritic, anti-inflammatory, antioxidant, chemopreventive, chemotherapeutic, and anti-infectious. Furthermore, curcumin can suppress inflammation; promote angiogenesis; and treat diabetes, pulmonary problems, and neurological dysfunction. Here, we review the effects of curcumin on astrocytes in NDs, with a focus on Alzheimer’s disease, Parkinson’s disease, multiple scleroses, Huntington’s disease, and amyotrophic lateral sclerosis.

show abstract

Potential Preventive Strategies for Amyotrophic Lateral Sclerosis

Cited by 14 publications

References 184 publications

The potential benefit of leptin therapy against amyotrophic lateral sclerosis (ALS)

The potential benefit of leptin therapy against amyotrophic lateral sclerosis (ALS)

Amyotrophic lateral sclerosis is a complicated challenge that needs distinct evaluation

The Functional Roles of Curcumin on Astrocytes in Neurodegenerative Diseases

Contact Info

Product

Resources

About